Our platform provides a comprehensive one-stop service, ranging from the establishment of tumor cell lines or disease models to efficacy testing, providing pharmacological animal models primarily focused on anti-tumor effects and disease model efficacy evaluation, with an emphasis on metabolic and autoimmune diseases.

  • Animal Cell Model:

    • Diverse mouse strains
    • 200+tumor cell lines
    • 80+tumor cell models
    • 24tumor indications
    • Continuously accumulating in vitro overexpressing cell lines
    • Immune reconstruction mice model screened by Donors
    • Tumor cell line construction or pre-formed tumor model development based on target and MOA
  • Disease Animal Model:

    • Diverse and abundant disease animal models
    • Experienced in establishingmetabolic and autoimmune disease models
    • Scientific guidance for selecting different animal disease models for the same indication
    • Collaboration to explore the development of diseases animal models based on the pathogenesis of the indications

PK research based on ELISA, FACS and other detection techniques, we can provide PK studies of various biologics including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), proteins, vaccines, etc., suitable for rodent animals and primates such as cynomolgus monkeys.

Service Features:

  • Exclusive and specific method development
  • Seamless connection between research and production teams to guide drug optimization and reduce pharmaceutical development risks
  • High quality assurance and high method reproducibility

Our platform offers early toxicology platforms and collaborating with high-quality CRO companies to conduct formal preclinical toxicology studies.

Service Features:

  • Meeting the diverse research needs of early toxicology studies for various biopharmaceuticals
  • Integrating high-quality in vivo pharmacology research resources
  • Obtaining IND approval in as fast as 10 months
  • Meeting regulatory requirements of multiple countries including FDA, NMPA, EMA, etc.

Bioanalysis platform, utilizing ELISA, FACS, IHC, and Pathology, is applicable for efficacy, pharmacokinetic, and safety evaluation studies of various biologics forms including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), proteins, and vaccines, utilizing rodents, non-human primates such as cynomolgus monkeys, and other primate models.

Service Features:

  • Diverse preclinical in vivo pharmacological bioanalytical technologies
  • Comprehensive analysis and research guidance for preclinical in vivo pharmacology based on bioanalysis
  • Competitive analysis and detection turnaround time
  • Professional bioanalytical capabilities for CGT novel drugs

One-Stop Service of in vivo Pharmacology


GenScript ProBio’s in vivo Pharmacology (IVP) Department offers clients an integrated IND project one-stop solution, covering in vivo efficacy, pharmacokinetics, safety evaluation, and more. By leveraging this cooperative model, our clients can benefit from a ready-to-go team of professionals. This seamless integration allows for a smooth connection between project CMC and in vivo pharmacology. As a result, we can expedite the IND submission process, with the capability to complete it within a remarkable 10-month timeframe. Moreover, we ensure compliance with regulatory requirements across multiple countries, meeting the standards set by NMPA, FDA, and EMA.

Service Content